Details of the Drug

General Information of Drug (ID: DM4M1SG)

Drug Name

Clarithromycin

Synonyms

Abbotic; Adel; Astromen; Biaxin; Bicrolid; CTY; Clacine; Clambiotic; Claribid; Claricide; Clarith; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Clathromycin; Cyllid; Cyllind; Helas; Heliclar; Klacid; Klaciped; Klaricid; Klarid; Klarin; Klax; Kofron; Mabicrol; Macladin; Maclar; Mavid; Naxy;Veclam; Zeclar; Biaxin HP; Biaxin XL; Biaxin filmtab; Biaxin xl filmtab; Clarithromycin extended release; Clarithromycin suspension or tablets; Klaricid Pediatric; Klaricid XL; TE031; A-56268; ANX-015; Abbott-56268; Biaxin (TN); Clacid (TN); Claridar (TN); Claripen (TN); Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; Crixan (TN); DRG-0099; Fromilid (TN);Infex (TN); Klabax (TN); Klaricid (TN); Klaricid H.P; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; SDP-015; TE-031; Vikrol (TN); CLM & IL-12; CRL-1605 & Clarithromycin; Clarithromycin & Interleukin-12; Klaricid H.P.; O(6)-methylerythromycin; Clarithromycin (JP15/USP/INN); Clarithromycin [USAN:INN:BAN:JAN]; Hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; (14R)-14-Hydroxyclarithromycin; 6-O-Methylerythromycin; 6-O-Methylerythromycin a

Indication

Disease Entry	ICD 11	Status	REF
Acute maxillary sinusitis	N.A.	Approved	[1]
Acute otitis media	AB00	Approved	[1]
Bacterial infection	1A00-1C4Z	Approved	[2]
Mycoplasma pneumoniae pneumonia	N.A.	Approved	[1]
Staphylococcus aureus infection	N.A.	Approved	[1]
Streptococcal pneumonia	N.A.	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[3]
Pneumonia caused by chlamydia	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antibiotics

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

748

Logarithm of the Partition Coefficient (xlogp)

3.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability: 55% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 7.3 mL/min/kg [6]
Elimination: 35% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.8 hours [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.13677 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.23% [6]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.5 L/kg [6]
Water Solubility: The ability of drug to dissolve in water is measured as 2 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Torsade de pointes	Not Available	KCNQ1	OT8SPJNX	[8]
Torsade de pointes	Not Available	MINK1	OTKB0RA8	[8]
-----------

Chemical Identifiers

Formula: C38H69NO13
IUPAC Name: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
Canonical SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
InChI: InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
InChIKey: AGOYDEPGAOXOCK-KCBOHYOISA-N

Cross-matching ID

PubChem CID: 84029
ChEBI ID: CHEBI:3732
CAS Number: 81103-11-9
DrugBank ID: DB01211
TTD ID: D0Z1ZM
VARIDT ID: DR00713
INTEDE ID: DR0336
ACDINA ID: D00134

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA)	TTUWYEA	NOUNIPROTAC	Binder	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[12]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[14]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[15]
Cytochrome c oxidase subunit 2 (COX2)	OTTMVBJJ	COX2_HUMAN	Gene/Protein Processing	[16]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[17]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Gene/Protein Processing	[14]
Integrin beta-4 (ITGB4)	OT28UK84	ITB4_HUMAN	Gene/Protein Processing	[18]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Gene/Protein Processing	[19]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[20]
Lanosterol synthase (LSS)	OT9W2SFH	LSS_HUMAN	Gene/Protein Processing	[14]
Misshapen-like kinase 1 (MINK1)	OTKB0RA8	MINK1_HUMAN	Drug Response	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Clarithromycin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Clarithromycin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[21]
-----------

Coadministration of a Drug Treating the Disease Different from Clarithromycin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Decreased metabolism of Clarithromycin caused by Ivosidenib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[22]
Midostaurin	DMI6E0R	Major	Decreased metabolism of Clarithromycin caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[23]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Clarithromycin caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[24]
Gilteritinib	DMTI0ZO	Major	Decreased metabolism of Clarithromycin caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[25]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Clarithromycin caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[26]
Ivabradine	DM0L594	Major	Decreased metabolism of Clarithromycin caused by Ivabradine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[27]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Bepridil.	Angina pectoris [BA40]	[28]
Dronedarone	DMA8FS5	Major	Decreased metabolism of Clarithromycin caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[27]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[29]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Posaconazole.	Aspergillosis [1F20]	[28]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Levalbuterol.	Asthma [CA23]	[30]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Pirbuterol.	Asthma [CA23]	[31]
Budesonide	DMJIBAW	Major	Decreased metabolism of Clarithromycin caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[32]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Clarithromycin caused by Aminophylline mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[33]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Retigabine.	Behcet disease [4A62]	[28]
Cariprazine	DMJYDVK	Major	Decreased metabolism of Clarithromycin caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[34]
Erdafitinib	DMI782S	Major	Decreased metabolism of Clarithromycin caused by Erdafitinib mediated inhibition of CYP450 enzyme.	Bladder cancer [2C94]	[35]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Clarithromycin caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[36]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Eribulin.	Breast cancer [2C60-2C6Y]	[28]
Talazoparib	DM1KS78	Major	Decreased clearance of Clarithromycin due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[24]
Ixabepilone	DM2OZ3G	Moderate	Decreased metabolism of Clarithromycin caused by Ixabepilone mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[37]
Lapatinib	DM3BH1Y	Major	Decreased metabolism of Clarithromycin caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
HKI-272	DM6QOVN	Major	Decreased metabolism of Clarithromycin caused by HKI-272 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[38]
LY2835219	DM93VBZ	Major	Decreased metabolism of Clarithromycin caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[39]
Esterified estrogens	DM9KZDO	Moderate	Decreased metabolism of Clarithromycin caused by Esterified estrogens mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Clarithromycin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Palbociclib	DMD7L94	Major	Decreased metabolism of Clarithromycin caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[41]
Quinestrol	DMJ6H1Z	Moderate	Decreased metabolism of Clarithromycin caused by Quinestrol mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Clarithromycin caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Bosutinib	DMTI8YE	Major	Decreased metabolism of Clarithromycin caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Trastuzumab Emtansine	DMU1LXS	Moderate	Decreased metabolism of Clarithromycin caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Macitentan	DMP79A1	Major	Decreased metabolism of Clarithromycin caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[42]
PF-04449913	DMSB068	Major	Decreased metabolism of Clarithromycin caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[43]
Vilanterol	DMF5EK1	Moderate	Decreased metabolism of Clarithromycin caused by Vilanterol mediated inhibition of CYP450 enzyme.	Chronic obstructive pulmonary disease [CA22]	[44]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[31]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[31]
Levomilnacipran	DMV26S8	Major	Decreased metabolism of Clarithromycin caused by Levomilnacipran mediated inhibition of CYP450 enzyme.	Chronic pain [MG30]	[45]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Clarithromycin due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[46]
Regorafenib	DMHSY1I	Moderate	Decreased metabolism of Clarithromycin caused by Regorafenib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[27]
Intedanib	DMSTA36	Moderate	Decreased metabolism of Clarithromycin caused by Intedanib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[47]
Drospirenone	DM1A9W3	Major	Decreased metabolism of Clarithromycin caused by Drospirenone mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[27]
Levonorgestrel	DM1DP7T	Moderate	Decreased metabolism of Clarithromycin caused by Levonorgestrel mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[27]
Ulipristal	DMBNI20	Minor	Decreased metabolism of Clarithromycin caused by Ulipristal mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[24]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Sevoflurane.	Corneal disease [9A76-9A78]	[28]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Probucol.	Coronary atherosclerosis [BA80]	[28]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Clarithromycin caused by Oxtriphylline mediated inhibition of CYP450 enzyme.	Cough [MD12]	[33]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Pasireotide.	Cushing syndrome [5A70]	[28]
Osilodrostat	DMIJC9X	Major	Decreased metabolism of Clarithromycin caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[24]
Ivacaftor	DMZC1HS	Major	Decreased metabolism of Clarithromycin caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[27]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Clarithromycin caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[48]
Rivaroxaban	DMQMBZ1	Moderate	Decreased clearance of Clarithromycin due to the transporter inhibition by Rivaroxaban.	Deep vein thrombosis [BD71]	[49]
Vilazodone	DM4LECQ	Major	Decreased metabolism of Clarithromycin caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[50]
OPC-34712	DMHG57U	Major	Decreased metabolism of Clarithromycin caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[51]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Clomipramine.	Depression [6A70-6A7Z]	[28]
Polatuzumab vedotin	DMF6Y0L	Major	Decreased metabolism of Clarithromycin caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[52]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Decreased metabolism of Clarithromycin caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[27]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[28]
Ospemifene	DMC4GEI	Moderate	Decreased metabolism of Clarithromycin caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[53]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Deutetrabenazine.	Dystonic disorder [8A02]	[54]
Ingrezza	DMVPLNC	Major	Additive CNS depression effects by the combination of Clarithromycin and Ingrezza.	Dystonic disorder [8A02]	[55]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Clarithromycin caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[56]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Clarithromycin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Clarithromycin caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[57]
Lacosamide	DMVM6QR	Moderate	Decreased metabolism of Clarithromycin caused by Lacosamide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[27]
Cannabidiol	DM0659E	Minor	Decreased metabolism of Clarithromycin caused by Cannabidiol mediated inhibition of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[24]
Bay 80-6946	DMLOS5R	Major	Decreased metabolism of Clarithromycin caused by Bay 80-6946 mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[58]
Tazemetostat	DMWP1BH	Major	Decreased metabolism of Clarithromycin caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[59]
Solifenacin	DMG592Q	Major	Decreased metabolism of Clarithromycin caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[27]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Clarithromycin caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[60]
Dexlansoprazole	DM1DBV5	Moderate	Decreased metabolism of Clarithromycin caused by Dexlansoprazole mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[61]
Ripretinib	DM958QB	Major	Decreased metabolism of Clarithromycin caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[27]
Sunitinib	DMCBJSR	Moderate	Decreased metabolism of Clarithromycin caused by Sunitinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[27]
Avapritinib	DMK2GZX	Major	Decreased metabolism of Clarithromycin caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[24]
Colchicine	DM2POTE	Major	Decreased metabolism of Clarithromycin caused by Colchicine mediated inhibition of CYP450 enzyme.	Gout [FA25]	[62]
Digitoxin	DMWVIGP	Moderate	Decreased clearance of Clarithromycin due to the transporter inhibition by Digitoxin.	Heart failure [BD10-BD1Z]	[63]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Clarithromycin caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[64]
Simeprevir	DMLUA9D	Major	Decreased metabolism of Clarithromycin caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[27]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Clarithromycin caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[64]
Daclatasvir	DMSFK9V	Major	Decreased metabolism of Clarithromycin caused by Daclatasvir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[24]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Clarithromycin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[65]
MK-1439	DM215WE	Minor	Decreased metabolism of Clarithromycin caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[66]
Fosamprenavir	DM4W9B3	Minor	Decreased metabolism of Clarithromycin caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[67]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[68]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Clarithromycin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Clarithromycin caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[69]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[70]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Clarithromycin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[71]
Rilpivirine	DMJ0QOW	Moderate	Decreased metabolism of Clarithromycin caused by Rilpivirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[72]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Clarithromycin caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[73]
Maraviroc	DMTL94F	Major	Decreased metabolism of Clarithromycin caused by Maraviroc mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[74]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Clarithromycin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[75]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Clarithromycin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[28]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Clarithromycin caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[27]
Aliskiren	DM1BV7W	Moderate	Decreased metabolism of Clarithromycin caused by Aliskiren mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[28]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Clarithromycin caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[28]
Tolvaptan	DMIWFRL	Major	Decreased metabolism of Clarithromycin caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[27]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Clarithromycin caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[76]
TP-434	DM5A31S	Minor	Decreased metabolism of Clarithromycin caused by TP-434 mediated inhibition of CYP450 enzyme.	Infectious gastroenteritis/colitis [1A40]	[77]
Berotralstat	DMWA2DZ	Major	Decreased clearance of Clarithromycin due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[78]
Suvorexant	DM0E6S3	Major	Decreased metabolism of Clarithromycin caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[27]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Clarithromycin caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[79]
ITI-007	DMUQ1DO	Major	Decreased metabolism of Clarithromycin caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[80]
Quazepam	DMY4D87	Moderate	Decreased metabolism of Clarithromycin caused by Quazepam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[81]
Estazolam	DMZGXUM	Moderate	Decreased metabolism of Clarithromycin caused by Estazolam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[81]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[24]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Phenolphthalein.	Irritable bowel syndrome [DD91]	[28]
Eluxadoline	DMYZ0P1	Moderate	Decreased metabolism of Clarithromycin caused by Eluxadoline mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[82]
Naloxegol	DML0B41	Major	Decreased metabolism of Clarithromycin caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[27]
Pemigatinib	DM819JF	Major	Decreased metabolism of Clarithromycin caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[24]
Crizotinib	DM4F29C	Major	Decreased metabolism of Clarithromycin caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[27]
Brigatinib	DM7W94S	Major	Decreased metabolism of Clarithromycin caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[83]
Ceritinib	DMB920Z	Major	Decreased metabolism of Clarithromycin caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[27]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Clarithromycin caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[84]
Osimertinib	DMRJLAT	Major	Decreased metabolism of Clarithromycin caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[85]
Pralsetinib	DMWU0I2	Major	Decreased clearance of Clarithromycin due to the transporter inhibition by Pralsetinib.	Lung cancer [2C25]	[86]
Capmatinib	DMYCXKL	Major	Decreased metabolism of Clarithromycin caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[87]
Selpercatinib	DMZR15V	Major	Decreased metabolism of Clarithromycin caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[24]
Artemether	DM48QOT	Major	Decreased metabolism of Clarithromycin caused by Artemether mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[27]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Halofantrine.	Malaria [1F40-1F45]	[88]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Hydroxychloroquine.	Malaria [1F40-1F45]	[89]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[24]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Clarithromycin and Idelalisib.	Mature B-cell leukaemia [2A82]	[90]
GDC-0199	DMH0QKA	Major	Decreased metabolism of Clarithromycin caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[91]
Acalabrutinib	DM7GCVW	Major	Decreased metabolism of Clarithromycin caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[92]
Ibrutinib	DMHZCPO	Major	Decreased metabolism of Clarithromycin caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[27]
Ponatinib	DMYGJQO	Major	Decreased metabolism of Clarithromycin caused by Ponatinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[27]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Clarithromycin due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[27]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Vemurafenib.	Melanoma [2C30]	[28]
Selumetinib	DMC7W6R	Major	Decreased metabolism of Clarithromycin caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[93]
LGX818	DMNQXV8	Major	Decreased metabolism of Clarithromycin caused by LGX818 mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[94]
Dabrafenib	DMX6OE3	Moderate	Decreased metabolism of Clarithromycin caused by Dabrafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[27]
Ubrogepant	DM749I3	Major	Decreased metabolism of Clarithromycin caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[95]
Rimegepant	DMHOAUG	Moderate	Decreased metabolism of Clarithromycin caused by Rimegepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[96]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Clarithromycin caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[97]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Siponimod.	Multiple sclerosis [8A40]	[27]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Fingolimod.	Multiple sclerosis [8A40]	[28]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Clarithromycin and Ozanimod.	Multiple sclerosis [8A40]	[98]
Deflazacort	DMV0RNS	Major	Decreased metabolism of Clarithromycin caused by Deflazacort mediated inhibition of CYP450 enzyme.	Muscular dystrophy [8C70]	[24]
Romidepsin	DMT5GNL	Moderate	Decreased metabolism of Clarithromycin caused by Romidepsin mediated inhibition of CYP450 enzyme.	Mycosis fungoides [2B01]	[99]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Clarithromycin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[24]
Nilotinib	DM7HXWT	Major	Decreased metabolism of Clarithromycin caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[27]
Dasatinib	DMJV2EK	Major	Decreased metabolism of Clarithromycin caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[27]
Vorapaxar	DMA16BR	Major	Decreased metabolism of Clarithromycin caused by Vorapaxar mediated inhibition of CYP450 enzyme.	Myocardial infarction [BA41-BA43]	[27]
E-2007	DMJDYNQ	Minor	Decreased metabolism of Clarithromycin caused by E-2007 mediated inhibition of CYP450 enzyme.	Neuropathy [8C0Z]	[24]
Entrectinib	DMMPTLH	Major	Decreased metabolism of Clarithromycin caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[27]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[24]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Lofexidine.	Opioid use disorder [6C43]	[28]
S-297995	DM26IH8	Moderate	Decreased metabolism of Clarithromycin caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[24]
Olaparib	DM8QB1D	Major	Decreased metabolism of Clarithromycin caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[27]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Rucaparib.	Ovarian cancer [2C73]	[28]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Triclabendazole.	Parasitic worm infestation [1F90]	[28]
Istradefylline	DM20VSK	Major	Decreased metabolism of Clarithromycin caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[100]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Clarithromycin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[101]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[102]
Lefamulin	DME6G97	Major	Decreased metabolism of Clarithromycin caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[103]
Ergonovine	DM0VEC1	Major	Decreased metabolism of Clarithromycin caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[104]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Clarithromycin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[105]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Degarelix.	Prostate cancer [2C82]	[24]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and ABIRATERONE.	Prostate cancer [2C82]	[24]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Clarithromycin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[106]
Relugolix	DMK7IWL	Major	Decreased metabolism of Clarithromycin caused by Relugolix mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[107]
Silodosin	DMJSBT6	Major	Decreased metabolism of Clarithromycin caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[27]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[28]
Ambrisentan	DMD1QXW	Minor	Decreased metabolism of Clarithromycin caused by Ambrisentan mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[108]
Riociguat	DMXBLMP	Moderate	Decreased clearance of Clarithromycin due to the transporter inhibition by Riociguat.	Pulmonary hypertension [BB01]	[27]
Everolimus	DM8X2EH	Major	Decreased clearance of Clarithromycin due to the transporter inhibition by Everolimus.	Renal cell carcinoma [2C90]	[27]
Axitinib	DMGVH6N	Major	Decreased metabolism of Clarithromycin caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[27]
Temsirolimus	DMS104F	Major	Increased metabolism of Clarithromycin caused by Temsirolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[27]
Ciclesonide	DM2NA4K	Moderate	Decreased metabolism of Clarithromycin caused by Ciclesonide mediated inhibition of CYP450 enzyme.	Respiratory system disease [CB40-CB7Z]	[109]
Upadacitinib	DM32B5U	Major	Decreased metabolism of Clarithromycin caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[110]
Tofacitinib	DMBS370	Major	Decreased metabolism of Clarithromycin caused by Tofacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[27]
Dexamethasone	DMMWZET	Moderate	Decreased metabolism of Clarithromycin caused by Dexamethasone mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[109]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Quetiapine.	Schizophrenia [6A20]	[111]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Clarithromycin caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[112]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Iloperidone.	Schizophrenia [6A20]	[28]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Paliperidone.	Schizophrenia [6A20]	[28]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Amisulpride.	Schizophrenia [6A20]	[113]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Asenapine.	Schizophrenia [6A20]	[28]
Avanafil	DM75CXN	Major	Decreased metabolism of Clarithromycin caused by Avanafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[27]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Clarithromycin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[114]
LDE225	DMM9F25	Major	Decreased metabolism of Clarithromycin caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[115]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Clarithromycin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[24]
Larotrectinib	DM26CQR	Major	Decreased metabolism of Clarithromycin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[27]
Docetaxel	DMDI269	Major	Decreased metabolism of Clarithromycin caused by Docetaxel mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[116]
Trabectedin	DMG3Y89	Major	Decreased metabolism of Clarithromycin caused by Trabectedin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[27]
Armodafinil	DMGB035	Minor	Decreased metabolism of Clarithromycin caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[27]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[117]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Clarithromycin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[28]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[24]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Clarithromycin caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[118]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Pitolisant.	Somnolence [MG42]	[28]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[28]
Pomalidomide	DMTGBAX	Moderate	Decreased metabolism of Clarithromycin caused by Pomalidomide mediated inhibition of CYP450 enzyme.	Systemic sclerosis [4A42]	[27]
Fostamatinib	DM6AUHV	Major	Decreased metabolism of Clarithromycin caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[119]
As-1670542	DMV05SW	Moderate	Decreased metabolism of Clarithromycin caused by As-1670542 mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[24]
Apixaban	DM89JLN	Moderate	Decreased clearance of Clarithromycin due to the transporter inhibition by Apixaban.	Thrombosis [DB61-GB90]	[27]
Brilinta	DMBR01X	Major	Decreased metabolism of Clarithromycin caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[27]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Lenvatinib.	Thyroid cancer [2D10]	[28]
Cabozantinib	DMIYDT4	Major	Decreased metabolism of Clarithromycin caused by Cabozantinib mediated inhibition of CYP450 enzyme.	Thyroid cancer [2D10]	[27]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Clarithromycin caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[24]
Elagolix	DMB2C0E	Major	Decreased metabolism of Clarithromycin caused by Elagolix mediated inhibition of CYP450 enzyme.	Uterine fibroid [2E86]	[120]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Clarithromycin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[121]
Fluticasone	DMGCSVF	Major	Decreased metabolism of Clarithromycin caused by Fluticasone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[122]
-----------


⏷ Show the Full List of 203 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Cis-vanillin 2,3-butanediol acetal	E00595	71587693	Flavoring agent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Glyceryl monostearate	E00310	24699	Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydrazine yellow	E00409	164825	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Vanillin	E00049	1183	Flavoring agent
Carmellose sodium	E00625	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium hydroxide	E00374	73981	Adsorbent; Buffering agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium sorbate	E00566	23676745	Antimicrobial preservative
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol distearate	E00395	110800	Emollient; Opacifying agent; Surfactant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sorbic acid	E00441	643460	Antimicrobial preservative
Sorbitan monooleate	E00503	9920342	Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Sucrose 1,6-distearate	E00593	71587490	Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 39 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Clarithromycin 500 mg tablet	500 mg	24 HR Extended Release Oral Tablet	Oral
Clarithromycin 250 mg tablet	250 mg	Oral Tablet	Oral
Clarithromycin 500 mg tablet	500 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Clarithromycin FDA Label
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early (ACHIEVE)
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9	Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
10	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11	Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. J Cyst Fibros. 2014 Mar;13(2):179-85.
12	Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73.
13	Drug Interactions Flockhart Table
14	A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
15	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
16	A genome-wide analysis of targets of macrolide antibiotics in mammalian cells. J Biol Chem. 2020 Feb 14;295(7):2057-2067. doi: 10.1074/jbc.RA119.010770. Epub 2020 Jan 8.
17	Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos. 2006 Oct;34(10):1742-8.
18	Effects of eight antibacterial agents on cell survival and expression of epithelial-cell- or cell-adhesion-related genes in human gingival epithelial cells. J Periodontal Res. 2004 Feb;39(1):50-8. doi: 10.1111/j.1600-0765.2004.00704.x.
19	Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother. 2005 Sep;56(3):502-6. doi: 10.1093/jac/dki251. Epub 2005 Jul 8.
20	T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest. 2001 Jun;107(11):1433-41. doi: 10.1172/JCI12118.
21	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
22	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
23	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
24	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
25	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
26	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
27	Cerner Multum, Inc. "Australian Product Information.".
28	Canadian Pharmacists Association.
29	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
30	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
31	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
32	Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
33	Amsden GW "Erythromycin, clarithromycin, and azithromycin: are the differences real?" Clin Ther 18 (1996): 56-72. [PMID: 8851453]
34	Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
35	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
36	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
37	Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
38	Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
39	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
40	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
41	Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42	Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
43	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44	Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
45	Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
46	Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
47	Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
48	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
49	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
50	Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
51	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
52	Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
53	Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
54	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
55	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
56	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
57	Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L "Single dose phenytoin clearance during erythromycin treatment." Res Commun Chem Pathol Pharmacol 46 (1984): 207-17. [PMID: 6515115]
58	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
59	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
60	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
61	Miura M, Tada H, Yasui-Furukori N, et al. "Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes." Chirality 17 (2005): 338-344. [PMID: 15856433]
62	Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
63	Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.?J Pharmacol Sci. 2010;113(4):315-324. [PMID: 20724802]
64	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
65	Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
66	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
67	Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84. [PMID: 10600086]
68	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
69	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
70	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
71	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
72	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
73	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
74	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
75	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
76	Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
77	Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
78	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
79	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
80	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
81	Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
82	Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
83	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
84	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
85	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
86	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
87	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
88	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
89	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
90	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
91	Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
92	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
93	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
94	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
95	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
96	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
97	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
98	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
99	Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
100	Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
101	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
102	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
103	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
104	Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7. [PMID: 314074]
105	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
106	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
107	Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
108	Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
109	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
110	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
111	DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
112	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
113	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
114	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
115	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
116	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
117	Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
118	Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
119	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
120	Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
121	Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
122	Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]